Steve Krognes has held significant stock options in Denali Therapeutics, where at one point he had options for 125,000 shares at a strike price of $5.28, set to expire in 2027. After transitioning to Pliant Therapeutics, Krognes forfeited all stock...

Steve Krognes has held significant stock options in Denali Therapeutics, where at one point he had options for 125,000 shares at a strike price of $5.28, set to expire in 2027. After transitioning to Pliant Therapeutics, Krognes forfeited all stock awards granted during his time as CFO of Denali, which reflects the shifting landscape of executive compensation where previous awards are often linked to employment status. At Pliant, he now holds options that will become available based on the company’s performance over time. Krognes' involvement in insider trading has been limited, which may suggest a cautious approach to managing his stock holdings, aiming to align with the performance of the company and its broader goals.